NCT06902857Active, not recruiting
Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)
Prospective Observational Study on the Predictive Value of Cardiac Damage Markers High-sensitivity Cardiac Troponin I (Hs-cTnI), N-terminal Pro-B-natriuretic Peptide (NT-proBNP) and Soluble Suppression of Tumorigenesis-2 (sST2) for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV).
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
The Diabetes-CV study is an observational study designed to assess the prognostic value of serum cardiac damage markers high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic peptide (NT-proBNP), and soluble suppression of tumorigenesis-2 (sST2) in predicting mortality, major adverse cardiovascular events, and diabetic complications in patients with type 2 diabetes.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 964 (actual)
- First submitted
- 24 Mar 2025
- Start date
- 18 Apr 2024
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
- Diseases
- Type 2 diabetes
- NCT number
- NCT06902857
What you commit to
- Study type: Observational
- Participants enrolled: 964
- From 18 Apr 2024 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- type 1 diabetes
- patients with active cancer or cancer in remission for less than 5 years
Other
- any medical or other reason that leads the investigator to consider the subject ineligible for the study.
Who the study is looking for
- type 2 diabetes
- patients attending the outpatient services
Age in the registry: 50 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS INRCA Hospital Coordinator of this site? Confirm its status | Ancona | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.